Affymetrix Shares Fall on Analyst Downgrade | GenomeWeb

NEW YORK (GenomeWeb News) – Shares in Affymetrix plummeted more than 13 percent in afternoon trading today on Nasdaq after an analyst from Barclay's Capital downgraded the firm from "equal weight" to "underweight."

Shares of Affymetrix were trading at $5.58 this afternoon, a decrease of $0.86 from yesterday's closing price of $6.44.

The Barclay's analyst downgraded Affymetrix's stock based on the recent introduction of competing technologies that are rendering Affymetrix's products "obsolete."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.